CoChat
Sign Up
Cited by 81Pharmacology and Obesity TreatmentBariatric Surgery and OutcomesDiabetes, Cardiovascular Risks, and Lipoproteins

Effect of orlistat on cardiovascular disease risk in obese adults

Swinburn, B. A., Carey, D., Hills, A. P., Hooper, M., Marks, S., Proietto, J., Strauss, B. J., Sullivan, D. +2 more·2005·Diabetes, Obesity and Metabolism
DOI 10.1111/j.1463-1326.2004.00467.x
Open this paper in CoChat — free account

Abstract

AIM: The aim of this study is to compare the effect of orlistat vs. placebo on the predicted 10-year cardiovascular disease (CVD) risk in obese people with one or more cardiovascular risk factors treated for 12 months, in conjunction with a fat-reduced, but otherwise ad libitum, diet. METHODS: A double-blind, randomized, placebo-controlled, parallel study was performed in conjunction with a fat-reduced diet and physical activity advice for 1 year. Participants (n = 339) from eight centres in Australia and New Zealand were randomized to either orlistat (120 mg) three times daily (n = 104 women, 66 men; mean +/- s.d. age = 52.0 +/- 7.5 years, body mass index (BMI) = 37.6 +/- 5.1 kg/m(2)) or placebo three times daily (n = 89 women, 80 men; age = 52.5 +/- 7.4 years, BMI = 38.0 +/- 4.9 kg/m(2)). The primary efficacy criterion was the 10-year risk of developing CVD calculated from the Framingham equation. Secondary efficacy criteria were body weight, waist circumference, blood pressure and serum concentrations of triglycerides, cholesterol (total, LDL and HDL), glucose, insulin and glycated haemoglobin and quality of life. RESULTS: There was no difference in the change in 10-year CVD risk between orlistat and placebo groups over 1 year. The orlistat group, however, had significant favourable changes in many of the individual CVD risk factors (total cholesterol, LDL-cholesterol, glucose, glycated haemoglobin, insulin, body weight and waist circumference) and one of the domains of quality of life measured by means of the SF-36 questionnaire (vitality), compared to the placebo group. Significant reductions in medication use for hypertension and diabetes were observed in the orlistat group, compared to those in placebo, but there were no significant differences in medication use for blood lipids. CONCLUSIONS: Orlistat may have reduced CVD risk, as judged by the favourable changes in individual risk factors and reductions in medication use, but the method used in order to measure absolute CVD risk in this study (Framingham CVD equation) was not sensitive enough to detect the changes in this relatively low-risk group (approximately 10% of risk of a CVD event over 10 years).

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2004.00467.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Swinburn, B. A., Carey, D., Hills, A. P., Hooper, M., Marks, S., Proietto, J., Strauss, B. J., Sullivan, D., Welborn, T. A., & Caterson, I. D.
Affiliations
  • University of Auckland (NZ)
  • The University of Queensland (AU)
  • Queensland University of Technology (AU)
  • The University of Sydney (AU)
  • Monash Medical Centre (AU)
  • The Royal Melbourne Hospital (AU)
  • Royal Prince Alfred Hospital (AU)
  • Sir Charles Gairdner Hospital (AU)
Corresponding author
Swinburn, B. A.
ORCID
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2005-04-04
Volume
7
Issue
3
Pages
254-262
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/j.1463-1326.2004.00467.x
OpenAlex
W1517951941
Cited by
81
References
2
Citations by year
2026: 2 · 2025: 6 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 2 · 2016: 5 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 3
FWCI
3.18
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Centre for Health Research; Faculty of Health; Institute of Health and Biomedical Innovation
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
orlistat, cardiovascular risk, obesity, ad libitum feeding, 10-year cardiovascular risk prediction, Framingham risk equation, cardiovascular risk factors, LDL cholesterol, HbA1c, insulin, blood pressure, quality of life, weight loss, medication use
MeSH terms
Orlistat, Adult, Aged, Antihypertensive Agents, Blood Glucose, Body Constitution, Cardiovascular Diseases, Cholesterol, Diet, Reducing, Double-Blind Method, Exercise Therapy, Female, Humans, Hypoglycemic Agents, Insulin, Lactones, Lipids, Cholesterol, LDL, Male, Middle Aged, Obesity, Probability, Risk Factors, Single-Blind Method, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review